Neovasc Inc. is a Canada-based specialty medical device company. The Company develops, manufactures, and markets products for the cardiovascular marketplace. The Company is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. The Company's products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary vasculature delivers an inadequate supply of blood to the heart muscle; and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel, and Europe. The Company operates through the development, manufacturing, and marketing of medical devices segment. Its wholly owned subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Neovasc Inc does not pay a dividend.
Price/Cash Flow (TTM)